Medigene participates at upcoming conferences

Planegg/Martinsried – Medigene AG ( http://www.medigene.com) (Medigene, FSE: MDG1, Prime Standard), an immuno-oncology company focusing on the development of T-cell-based cancer therapies, will participate at the following upcoming science and investor conferences. Medigene’s management and/or scientists will be available for one-on-one meetings at these events.

64th ASH Annual Meeting
10-13 December 2022
New Orleans, LA, USA
https://www.hematology.org/meetings/annual-meeting

LifeSci 12th Annual Corporate Access Event
9-11 January 2023
San Francisco, CA, USA

Medigene’s management will be available for one-on-one meetings at this event.

— end of press release —

About Medigene

Medigene AG (FSE: MDG1) is a late pre-clinical stage immuno-oncology company, focusing on discovering and developing differentiated, breakthrough cellular therapies to improve the lives of cancer patients. With an end-to-end technology platform built on multiple proprietary and exclusive product enhancement and product development technologies, Medigene aims to create best-in-class T cell receptor-modified T cell (TCR-T) therapies that are optimized for both safety and efficacy. Our strategy is to develop product candidates both for our in-house therapeutics pipeline and for partnering.

For more information, please visit http://www.medigene.com

This press release contains forward-looking statements representing the opinion of Medigene as of the date of this release. The actual results achieved by Medigene may differ significantly from the forward-looking statements made herein. Medigene is not bound to update any of these forward-looking statements. Medigene® is a registered trademark of Medigene AG. This trademark may be owned or licensed in select locations only.

Medigene

Phone: +49 89 2000 3333 01
E-mail: investor@medigene.com

LifeSci Advisors

Sandya von der Weid
Phone: +41 78 680 05 38
E-mail: svonderweid@lifesciadvisors.com

This site is registered on wpml.org as a development site.